$1.94
-0.05 (-2.51%)
Open$1.98
Previous Close$1.99
Day High$1.98
Day Low$1.87
52W High$21.00
52W Low$1.33
Volume—
Avg Volume115.2K
Market Cap8.34M
P/E Ratio—
EPS$-5.99
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+916.5% upside
Current
$1.94
$1.94
Target
$19.72
$19.72
$18.07
$19.72 avg
$32.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 850.6K | 846.2K | 822.4K |
| Net Income | -189,460 | -228,334 | -201,883 |
| Profit Margin | -22.3% | -27.0% | -24.6% |
| EBITDA | -320,116 | -324,230 | -315,475 |
| Free Cash Flow | -189,627 | -182,540 | -129,892 |
| Rev Growth | +3.9% | -4.1% | +22.7% |
| Debt/Equity | 0.68 | 0.61 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |